glp-1 and afib Multiple drugs linked to lower risk Glucagon-like peptide-1 receptor agonists and

Potere Health MD serves patients throughout Cedar City and Iron County, including Enoch, Parowan, Brian Head, New Harmony, Kanarraville, and nearby Southern Utah communities

By reducing appetite and supporting healthier eating habits, GLP-1s make long-term weight loss more realistic for many patients

In December 2020, the FDA issued approval for the drug to be used in adolescents as young as 12 years old with a body weight above 132 pounds (60 kg) with obesity

Researchers at Johns Hopkins University are expected to commence a multi-site, double-blind, randomized, placebo-controlled study examining the effect of GLP-1s on brain volume via MRI as well as other blood-based biomarkers